A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial).

Trial Profile

A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms Renal EFFECT Trial
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Mar 2012 Results published in the Journal of Clinical Oncology.
    • 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
    • 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top